FOLFIRINOX, which adds oxaliplatin over the FOLFIRI regimen, should be evaluated for the impact of UGT1A1 on PC patients with poorer prognosis than CRC patients. This evidence concerns the gene UGT1A1 and pachyonychia congenita.